H
Highlight Therapeutics
Biotech & Life Sciences · Paterna, Spain · Founded 2010
A private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology MoreLess
Highlight Therapeutics is a private, clinical-stage biotechnology company focused on developing RNA-based immuno-oncology therapies. The company's main program is BO-112, a synthetic double-stranded RNA that mimics a viral infection, which is designed to be injected directly into a tumor to activate the innate immune system and enhance the efficacy of other cancer treatments, including checkpoint inhibitors.
The company's business model is centered on the research and development of these novel cancer therapies. Highlight Therapeutics aims to partner with larger pharmaceutical companies for late-stage development, commercialization, and marketing of its products. The company's target market is the oncology sector, specifically focusing on patients with solid tumors who are not responding to or have relapsed after treatment with checkpoint inhibitors. By targeting this patient population, the company is addressing a significant unmet medical need in the cancer treatment landscape.
Highlight Therapeutics was founded in 2010 and is based in Paterna, Spain. The company has raised Series B funding and is actively advancing its clinical programs to bring its innovative therapies to market.
Keywords: immuno-oncology, RNA-based therapies, cancer treatment, clinical-stage, biotechnology, solid tumors, checkpoint inhibitors, innate immune system, intratumoral injection, drug development
Company overview
Highlight Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2010
- Headquarters
- Paterna, Spain
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 79.7
Valuation & funding
Highlight Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Sep 2025 | $17M | — | Buenavista Equity Partners | ↗ |
| LATE VC✓Equity / VC | Feb 2021 | $25M | $99M | CDTI Innvierte · Columbus Venture Partners · Advent Life Sciences | — |
| OtherOther financing | Mar 2013 | $0 | — | Realiza Business Angels | — |
| OtherOther financing | Mar 2011 | $0 | — | Realiza Business Angels | — |
| SPINOUT✓Other financing | Apr 2010 | $0 | — | CNIO | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin | Profit | Margin |
|---|---|---|---|---|
| 2026 | −$1.3M | — | −$4.5M | — |
| 2025 | −$1.3M | — | −$4.5M | — |
| 2024 | −$1.3M | — | −$4.5M | — |
| 2023 | −$1.3M | — | ||
| 2022 | −$1.3M | — | ||
| 2021 | −$1.3M | — | ||
| 2020 | −$1.3M | — |
Growth signals
Highlight Therapeutics website traffic
Latest recorded traffic for Highlight Therapeutics is 1K monthly website visits, up 185.7% over the last three months. Highlight Therapeutics's team declined 5.6% over the past year.
Comparisons
Highlight Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Highlight Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Highlight Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Highlight Therapeutics has talent and traffic
team presence
In the news
Latest news about Highlight Therapeutics
Recent press, funding announcements, and product moves mentioning Highlight Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Highlight Therapeutics
An AI-synthesized read of the highest-engagement posts about Highlight Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Highlight Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.